X4 Pharmaceuticals, IncXFOREarnings & Financial Report
Nasdaq
XFOR Q3 2025 Key Financial Metrics
Revenue
$1.8M
Gross Profit
$1.4M
Operating Profit
$-27.5M
Net Profit
$-29.8M
Gross Margin
80.1%
Operating Margin
-1558.6%
Net Margin
-1689.2%
YoY Growth
215.2%
EPS
$-0.69
Financial Flow
X4 Pharmaceuticals, Inc Q3 2025 Financial Summary
X4 Pharmaceuticals, Inc reported revenue of $1.8M for Q3 2025, with a net profit of $-29.8M (-1689.2% margin). Cost of goods sold was $351.0K, operating expenses totaled $28.9M.
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-29.8M |
| Gross Margin | 80.1% |
| Operating Margin | -1558.6% |
| Report Period | Q3 2025 |
X4 Pharmaceuticals, Inc Annual Revenue by Year
X4 Pharmaceuticals, Inc annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.6M |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $700000 | $560000 | $1.3M | $28.8M | $2.0M | $1.8M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | 181.9% | 215.2% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $173.3M | $112.2M | $210.6M | $178.2M | $146.4M | $130.0M | $105.2M | $163.6M |
| Liabilities | $105.7M | $111.1M | $116.2M | $118.5M | $124.3M | $107.1M | $101.2M | $101.9M |
| Equity | $67.6M | $1.0M | $94.5M | $59.6M | $22.1M | $22.9M | $4.0M | $61.6M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-68.8M | $-33.6M | $-63.9M | $-34.0M | $628000 | $-12.4M | $-29.9M | $-27.8M |